$ k4 ]6 y% K; D" R现在，美国西雅图弗莱德哈钦森癌症研究中心的科琳·德兰尼领导的研究团队使用了一种蛋白质，可将每千克血液中干细胞的数量从20万增加到了6亿。德兰尼表示，当这些干细胞被移植到病人体内时，它们能够很快生成白血细胞以及血液系统中的其他元素。, x$ |7 [' T+ M! J. N7 K
8 t5 ~8 Q, y4 ?, n研究结果表明，将含有更多干细胞的血液移植入人体后，这些细胞14天就可以“落叶生根”，生成白血细胞，而没有经过“增殖”的干细胞则需要4周。参与该实验的10个白血病患者中，有7名患者仍然活着，也没有显示出旧病复发的迹象。3 X' C" c. H* N- d8 U9 s
. D0 q& O: X$ j- e I( p
英国慈善机构安东尼诺兰信托的首席执行官亨利·布兰德表示，该技术的潜力非常“巨大”。她认为，脐带血是一座未被开发的“宝矿”，在治疗白血病以及再生医学等方面均有广泛的用途。 & }9 e* B1 ^) |3 _+ Q 5 g7 k3 {" O# g( H6 m, P+ }原始出处： : U7 `: p+ d; E: e6 I0 u+ Y6 k " \) G1 A+ W8 C9 ^$ C; X: D% k5 pNature Medicine 17 January 2010 | doi:10.1038/nm.2080 9 w( s0 }* W$ z% v/ q% J+ j, E* a& C 2 ?* S0 J/ K. p8 o& k; B( F3 ^3 iNotch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution 3 U+ C' B! w4 c! R" c9 M( H. z% Q+ {6 V, {
Colleen Delaney1,2, Shelly Heimfeld1, Carolyn Brashem-Stein1, Howard Voorhies1, Ronald L Manger1 & Irwin D Bernstein1,2" n5 ?1 s3 f6 I( N* o3 z+ u
3 Y- L- V& ` {% W3 x) s( F; H
Delayed myeloid engraftment after cord blood transplantation (CBT) is thought to result from inadequate numbers of progenitor cells in the graft and is associated with increased early transplant–related morbidity and mortality. New culture strategies that increase the number of cord blood progenitors capable of rapid myeloid engraftment after CBT would allow more widespread use of this stem cell source for transplantation. Here we report the development of a clinically relevant Notch-mediated ex vivo expansion system for human CD34+ cord blood progenitors that results in a marked increase in the absolute number of stem/progenitor cells, including those capable of enhanced repopulation in the marrow of immunodeficient nonobese diabetic–severe combined immunodeficient (NOD-SCID) mice. Furthermore, when cord blood progenitors expanded ex vivo in the presence of Notch ligand were infused in a clinical setting after a myeloablative preparative regimen for stem cell transplantation, the time to neutrophil recovery was substantially shortened. To our knowledge, this is the first instance of rapid engraftment derived from ex vivo expanded stem/progenitor cells in humans. , A! B5 Y8 C' G. Y; K* s9 }% x8 H6 I
1 Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.8 d w; r& P6 G0 q4 ]
2 Department of Pediatrics, University of Washington, Seattle, Washington, USA.作者: chb611301 时间: 2010-6-30 10:34